Pulmonary delivery of opioids as pain therapeutics

Advanced Drug Delivery Reviews

Volumn 58, Issue 9-10, 2006, Pages 1076-1088

  Farr, Stephen J ^a   Otulana, Babatunde A ^a  

^a ARADIGM CORPORATION   (United States)

Author keywords

Aerosol; Efficacy; Opioids; Pain management; Pharmacokinetics; Pulmonary

Indexed keywords

AEROSOLS; BIOMEDICAL ENGINEERING; DRUG DOSAGE; IMMUNOLOGY; MOLECULAR DYNAMICS; PHARMACOKINETICS;

EFFICACY; OPIOIDS; PAIN MANAGEMENT;

CONTROLLED DRUG DELIVERY;

ANILERIDINE; CODEINE; DIAMORPHINE; FENTANYL; HYDROMORPHONE; MORPHINE; MORPHINE 6 GLUCURONIDE; MORPHINE SULFATE; OPIATE;

ANALGESIA; BRONCHOSPASM; CLINICAL TRIAL; COUGHING; DIZZINESS; DOSE RESPONSE; DROWSINESS; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LITERATURE; LUNG; METERED DOSE INHALER; NAUSEA; NEBULIZATION; NEBULIZER; PAIN; POSTOPERATIVE PAIN; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; VOMITING;

ADMINISTRATION, INHALATION; ANALGESICS, OPIOID; DRUG DELIVERY SYSTEMS; HUMANS; LUNG; PAIN;

EID: 33750690664     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2006.07.013     Document Type: Review

References (33)

1. Farncombe M., Charter S., and Gillin A. The use of nebulized opioids for breathlessness: a chart review. Palliat. Med. 8 (1994) 306-312
2. Farncombe M., and Charter S. Case studies outlining use of nebulized morphine for patients with end-stage chronic lung and cardiac disease. J. Pain Symptom Manage. 8 (1993) 221-225
3. Young I.H., Davaskis E., and Keena V.A. Effect of low dose nebulized morphine on exercise endurance in patients with chronic lung disease. Thorax 44 (1989) 387-390
4. Massod A.R., Reed J.W., and Thomas S.H.L. Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 50 (1995) 629-634
5. Noseda A., Carpiaux J.-P., Markstein C., Meyvaert A., and de Maertelaer V. Disabling dyspnoea in patients with advanced disease; lack of effect of nebulized morphine. Eur. Respir. J. 10 (1997) 1079-1083
6. Zebraski S.E., Kochenash S.M., and Raffa R.B. Lung opioid receptors: pharmacology and possible target for nebulized morphine in dyspnea. Life Sci. 66 (2000) 2221-2231
7. Gutstein H.B., and Akil H. Opioid analgesics. In: Hardman J.G., Limbird L.E., and Gilman A.G. (Eds). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 10th ed. (2001), McGraw-Hill 569-619
8. Muijsers R.B.R., and Wagstaff A.J. Transdermal fentanyl: an updated review of its pharmacological properties and therapeutic efficacy in chronic cancer pain control. Drugs 6 (2001) 2289-2307
9. Byron P.R. Determinants of drug and polypeptide bioavailability from aerosols delivered to the lung. Adv. Drug Deliv. Rev. 5 (1990) 107-132
10. Otulana T., and Thipphawong J. In: Byron P.R., Dalby R., Peart and J., and Farr S.J. (Eds). Systemic delivery of small molecules: product development issues focused on pain therapeutics. Respiratory Drug Delivery VIII vol. 1 (2002), DHI Publishing 51-59
11. Chrubasik J., Ŵust H., Friedrich G., and Geller E. Absorption and bioavailability of nebulized morphine. Br. J. Anaesth. 61 (1988) 228-230
12. Masood A.R., and Thomas S.H.L. Systemic absorption of nebulized morphine compared with oral morphine in healthy subjects. Br. J. Clin. Pharmacol. 41 (1996) 250-252
13. Gonda I., Schuster J.A., Rubsamen R.M., Lloyd P., Cipolla D., and Farr S.J. Inhalation delivery systems with compliance and disease management capabilities. J. Control. Release 53 (1998) 269-274
14. Farr S.J., Warren S.J., Lloyd P., Okikawa J.K., Schuster J.A., Rowe A.M., Rubsamen R.M., and Taylor G. Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int. J. Pharm. 198 (2000) 63-70
15. Ward M.E., Woodhouse A., Mather L.E., Farr S.J., Okikawa J.K., Lloyd P., Schuster J.A., and Rubsamen R.M. Morphine pharmacokinetics after pulmonary administration from a novel aerosol delivery system. Clin. Pharmacol. Ther. 62 (1997) 596-609
16. Dershwitz M., Walsh J.L., Morishige R.J., Connors P.M., Rubsamen R.M., Shafer S.L., and Rosow C.E. Pharmacokinetics and pharmacodynamics of inhaled versus intravenous morphine in healthy volunteers. Anesthesiology 93 (2000) 619-628
17. Doenicke A., Moss J., Lorenz W., and Hoernecke R. Intravenous morphine and nalbuphine increase histamine and catechol release without accompanying hemodynamic changes. Clin. Pharmacol. Ther. 58 (1995) 81-89
18. Otulana B., Okikawa J., Linn L., Morishige R., and Thipphawong J. Safety and pharmacokinetics of inhaled morphine delivered using the AERx system in patients with moderate-to-severe asthma. Int. J. Clin. Pharmacol. Ther. 42 (2004) 456-462
19. Worsley M.H., Macleod A.D., Brodie M.J., Asbury A.J., and Clark C. Inhaled fentanyl as a method of analgesia. Anaesthesia 45 (1990) 449-451
20. Harvey C.J., O'Doherty M.J., Page C.J., Thomas S.H.L., Nunan T.O., and Treacher D.F. Comparison of jet and ultrasonic nebulizer pulmonary aerosol deposition during mechanical ventilation. Eur. Respir. J. 10 (1997) 905-909
21. Mather L.E., Kam P.C., Morishige R.J., Otulana B.A., Dayton F., and Rubsamen R.M. Pharmacokinetics of orally inhaled fentanyl in healthy subjects. J. Clin. Pharmacol. 40 (2000) 1060
22. Liu K., Dayton F., Shi S., Farr S.J., and Gonda I. Development of fentanyl citrate AERx™ system for pulmonary delivery. Pharm. Sci. 2 (1999)
23. Hung O.R., Whynot S.C., Varvel J.R., Shafer S.L., and Mezei M. Pharmacokinetics of inhaled liposome-encapsulated fentanyl. Anesthesiology 83 (1995) 277-284
24. Taylor K.M.G., Taylor G., Kellaway I.W., and Stevens J. The influence of liposomal encapsulation on sodium cromoglycate pharmacokinetics in man. Pharm. Res. 6 (1989) 633-636
25. Mather L.E., Woodhouse A., Ward M.E., Farr S.J., Rubsamen R.M., and Eltherington L. Pulmonary administration of aerosolized fentanyl: pharmacokinetic analysis of systemic delivery. J. Clin. Pharmacol. 46 (1998) 37-43
26. Chandler S. Nebulized opioids to treat dyspnea. Am. J. Hospice Palliat. Care 16 (1999) 418-422
27. Higgins M.J., Asbury A.J., and Brodie M.J. Inhaled nebulised fentanyl for postoperative analgesia. Anaesthesia 46 (1991) 973-976
28. Thipphawong J., Babul N., Morishige R., Findlay H., Reber K., Millward G., and Otulana B. Analgesic efficacy of inhaled morphine in patients after bunionectomy surgery. Anesthesiology 99 (2003) 693-700
29. Slatkin N., Rauck R., Koczwara B., Chevlen E., Thipphawong J., Morishige R., Otulana B., Beckman R., and Gonda I. Analgesic efficacy of inhaled morphine delivered with the AERx™ mPMS for breakthrough cancer pain. J. Pain 3 suppl. 1 (2002) 43
30. Boyle F., Mather L.E., Lam J., Morishige R.J., Otulana B.A., Dayton F., Rubsamen R.M., and Thipphawong J. Inhaled fentanyl via the AERx™ system for the treatment of breakthrough cancer pain. Proceedings of the 19th Annual Scientific Meeting (2000), American Pain Society, Atlanta GA
31. Hughes S., and Caverly P.M. Heroin inhalation and asthma. Br. Med. J. 297 (1988) 1511-1512
32. Letter to Health Care Professionals. Purdue Pharma. July 25, 2001.
33. Gonda I., Fiore M., Johansson E.T., Liu K., Morishige R.J., Okikawa B.A., Otulana B.A., and Rubsamen R.M. Bolus delivery of morphine solutions with the AERx pain management system (PMS). J. Aerosol Med. 12 (1999) 114